Introduction
============

Colorectal cancer (CRC) is the fourth most common cancer in China, with 331,300 new cases and 159,300 disease-related deaths in 2012 ([@ref-6]). The morbidity has increased steadily due to the growth of an aging population and the change of lifestyle in recent years, however, the exact mechanism and related predicted biomarkers are largely unknown.

During the past decades, microsatellite instability (MSI) and *RAS* mutation have been well studied as two prevalent genetic biomarkers involved in colorectal carcinogenesis. The mismatch repair (MMR) system, which includes the proteins MLH1, MSH2, MSH6 and PMS2, can repair incorrect base-pairing or unmatched DNA loops to maintain genomic stability. MSI is caused by a deficient mismatch repair (dMMR) system, which leads to a high rate of mutations in repeat sequences and accounts for approximately 15% of all CRCs as well as virtually all Lynch syndrome (LS) patients ([@ref-15]; [@ref-34]; [@ref-56]). Tumors with high level microsatellite instability (MSI-H) caused by germ line mutations or epigenetic silencing of MMR genes have unique clinicopathological characteristics ([@ref-7]). In early stage CRC, patients with MSI-H demonstrated favorable prognosis compared to those with low level of microsatellite instability (MSI-L) and microsatellite stability (MSS) ([@ref-42]; [@ref-51]), however, these patients did not benefit from fluoropyrimidine-based adjuvant chemotherapy ([@ref-42]; [@ref-47]).

The *RAS* gene family, the other significant biomarker, includes *KRAS*, *NRAS* and *HRAS*, and is located downstream in the epidermal growth factor receptor (EGFR) signal pathway. Mutations in the *RAS* gene, which are thought to occur early in the adenoma-carcinoma continuum, activate the *RAS*/MAPK pathway independently of EGFR activation, leading to poor response to EGFR inhibitors ([@ref-1]; [@ref-41]). Moreover, National Comprehensive Cancer Network (NCCN) clinical practice guidelines suggested that *KRAS* and *NRAS* gene mutations should be detected for metastatic CRC (mCRC) patients before treatment with Cetuximab and Panitumumab ([@ref-13]).

The status of dMMR and *RAS* mutation has been widely studied in western countries. The frequency of dMMR CRCs ranged from 15--20% ([@ref-16]; [@ref-51]; [@ref-52]), *KRAS* mutation ranged from 20--50% ([@ref-10]; [@ref-35]; [@ref-38]; [@ref-44]; [@ref-48]) and *NRAS* mutation was noted in less than 5% ([@ref-10]; [@ref-38]; [@ref-39]; [@ref-46]). However, studies in China showed a lower frequency of dMMR compared with that in western populations, and the clinicopathological characteristics were also inconsistent ([@ref-19]; [@ref-23]; [@ref-54]). Although several studies reported the frequency of *KRAS* mutation in Chinese CRC patients, the number of samples was limited in most of these studies ([@ref-49]; [@ref-54]; [@ref-55]). Moreover, information about *NRAS* mutation in Chinese CRC patients was limited. Little has been studied on the association between status of dMMR and *RAS* mutation. Therefore, in the present study, we analyzed the dMMR and *RAS* mutation status of CRC patients to evaluate possible associations between dMMR, *RAS* mutation and the clinicopathological characteristics in primary colorectal carcinoma and we also attempted to explore the prognostic roles of dMMR and *RAS* mutation.

Materials and Methods
=====================

Eight hundred and thirteen formalin-fixed, paraffin-embedded tumor specimens from CRC patients who underwent primary surgical resection from 2013 to 2016 in the Affiliated Hospital of Qingdao University were selected for this study. The patients' selection method is presented in a consort diagram ([Fig. 1](#fig-1){ref-type="fig"}). Patients who had undergone preoperative radiotherapy, chemotherapy and/or EGFR-targeted therapy were not included in this study.

![Consort diagram in patient selection.](peerj-06-4341-g001){#fig-1}

The clinical and pathologic variables were extracted from medical records and pathological reports, which included age, gender, primary locations of tumor, tumor diameter, histological characteristics, TNM stage, smoking status, drinking status and family medication history. The patients were followed up until October 2017, and the data concerning cancer recurrence and patient survival were collected. Patients diagnosed with stage I--III colorectal carcinoma were used to explore the prognostic role of dMMR and *RAS* mutation with disease-free survival (DFS) and overall survival (OS).

Primary locations of tumors were divided into the right side colon (from the cecum through the transverse colon), the left side colon (from the splenic flexure through the rectosigmoid flexure) and the rectum. Tumors were staged according to the criteria of the seventh edition of the American Joint Commission on Cancer (AJCC) TNM staging system. Mucinous adenocarcinoma and signet-ring cell carcinomas were recorded as mucin-producing tumors.

The study was approved by the Ethics Committee of the Affiliated Hospital of Qingdao University (No.20130049) and all patients had signed informed consent.

Immunohistochemistry for MMR proteins
-------------------------------------

As previously described ([@ref-31]), all specimens were fixed in 10% neutral buffered formalin and embedded in paraffin blocks. 3 µm-thick tissue sections were used for immunohistochemical analysis. Immunohistochemical staining was performed on an Automated Staining System (BenchMark XT, Ventana Medical Systems, Inc., Tucson, AZ, USA) according to the manufacturer's instructions. The ready-to-use antibodies were used as follows: MLH1 (No.M1, Ventana Medical Systems Inc, Tucson, AZ, USA, working solution), PMS2 (No.EPR3947, Ventana Medical Systems Inc, Arizona, USA, working solution), MSH2 (No.G219-1129, Ventana Medical Systems Inc, Tucson, AZ, USA, working solution), MSH6 (No.44, Ventana Medical Systems Inc, Tucson, AZ, USA, working solution).

The results were analyzed by two pathologists. Any tumor cell with nuclear staining was recorded as positive staining. Intact expression for all these proteins was regarded as proficient MMR (pMMR). Protein expression was defined as abnormal when nuclear staining of tumor cells was absent in the presence of positive staining in stromal cells and lymphocytes ([Fig. 2](#fig-2){ref-type="fig"}). The standard criteria for diagnosis of dMMR was as follows: dMMR in MLH1: loss of MLH1 and PMS2; dMMR in MSH2: loss of MSH2 and MSH6; dMMR in MSH6: loss of MSH6; dMMR in PMS2: loss of PMS2 ([@ref-43]).

![Immunohistochemical staining for mismatch repair proteins in one case of colorectal carcinoma.\
Tumor cells with absent MLH1 (A) and PMS2 (B) expression, and with MSH2 (C) and MSH6 (D) expression, which were regarded as deficient MMR. Note the presence of positive staining in stromal cells and lymphocyte serving as internal positive controls.](peerj-06-4341-g002){#fig-2}

Analysis of *KRAS* and *NRAS* gene mutations by ARMS-PCR
--------------------------------------------------------

Formalin-fixed, paraffin-embedded tumor sections were deparaffinized and air dried, and DNA was extracted using the Tiangen Blood and Tissue Kit (TiangenInc, Beijing, China). *KRAS* (codons12 and 13) and *NRAS* (codons12, 13 and 61) mutations were detected by amplification refractory mutation system in multiple quantitative polymerase chain reaction (ARMS-multi-qPCR) analysis with the Human *KRAS* and *NRAS* Mutation Detection kit (YuanQi Bio-Pharmaceutical Co., Ltd. Shanghai, China). The mutation points detected by this kit are listed in [Supplemental Information 2](#supp-2){ref-type="supplementary-material"}. Codons of *RAS* were amplified as described previously ([@ref-12]). Briefly, 3 µl sample DNA was amplified in a 25 µl reaction containing 9 µl of Mix1 and 13 µl of PCRMix3. Positive and negative controls for each sample were run simultaneously. The program for the PCR amplification flanking *KRAS* mutation site was as follows: 1 cycle at 42 °C for 5 min; 1 cycle at 94 °C for 3 min; 40 cycles at (94 °C for 15 s; 60 °C for 60 s). Fluorescence signals were collected at 60 °C. The program for the PCR amplification flanking *NRAS* mutation site was as follows: 1 cycle at 42 °C for 5 min; 1 cycle at 94 °C for 3 min; 40 cycles at (94 °C for 45 s; 60 °C for 80 s). Fluorescence signals were collected at 60 °C. The mutations were identified with a specific probe labeled with Hydroxy fluorescein (FAM). Amplicons were detected using ABI7500 Fast Real-Time PCR System (Thermo Fisher Scientific Inc., Waltham, MA, US).

Statistical analysis
--------------------

Results were analyzed with SPSS 19.0 (SPSS, Inc, Chicago, IL, USA). For comparison of the frequencies among groups, the Chi-square test and the Fisher exact test were used. Survival curves for DFS and OS were estimated using Kaplan--Meier analysis with the log-rank test. Probability (*p*) value \<0.05 was considered as statistical significance.

Results
=======

Patient characteristics
-----------------------

The main characteristics of the patients are summarized in the [Table 1](#table-1){ref-type="table"}. There were 506 (62.24%) males and 307 (37.76%) females with a mean age of 64 years. The majority of the patients (87.7%) were older than 50 years. 11.69%, 40.84%, 37.15% and 10.33% of patients presented with stage I, stage II, stage III and stage IV disease, respectively. The primary location was more common in rectum (54.49%). There were 283 (34.81%) patients with a smoking history and 165 (20.3%) patients with an alcohol in-taking history, respectively. There were 133 (16.36%) patients with mucin-productive carcinoma.

10.7717/peerj.4341/table-1

###### Clinicopathological information of the studied patients (*n* = 813).

![](peerj-06-4341-g005)

  Characteristics             Number   (%)
  --------------------------- -------- -------
  Gender                               
  Male                        506      62.24
  Female                      307      37.76
  Age                                  
  \<50                        100      12.3
  ≥50                         713      87.7
  Location                             
  Right side colon            181      22.26
  Left side colon             189      23.25
  Rectum                      443      54.49
  Mucin production                     
  With                        133      16.36
  Without                     680      83.64
  Tumor differentiation                
  Poor                        138      16.97
  moderate                    599      73.68
  Well                        33       4.06
  Unknown                     43       5.29
  Tumor stage                          
  I                           95       11.69
  II                          332      40.84
  III                         302      37.15
  IV                          84       10.33
  Bowel wall invasion (T)              
  T1                          21       2.58
  T2                          104      12.79
  T3                          336      41.33
  T4                          352      43.3
  Lymph node metastasis (N)            
  N0                          458      56.33
  N1                          203      24.97
  N2                          152      18.7
  Distant metastasis (M)               
  M0                          729      89.67
  M1                          84       10.33
  Lymphovascular invasion              
  Yes                         339      41.7
  No                          462      56.83
  Unknown                     12       1.47
  Alcohol intake                       
  Ever                        165      20.3
  Never                       648      79.7
  Smoking                              
  Ever                        283      34.81
  Never                       530      65.19
  Colorectal family history            
  Yes                         48       5.9
  No                          337      41.45
  Unknown                     428      52.65

MMR status and associations with clinicopathological characteristics
--------------------------------------------------------------------

MMR status was successfully evaluated in 797 patients. 121 (15.18%) patients exhibited dMMR. The rates of dMMR deficiency in MLH1, PMS2, MSH2 and MSH6 were 9.78% (78/797), 1.25% (10/797), 3.26% (26/797) and 0.87% (7/797), respectively. The rates of deficiency in MLH1/PMS2 and MSH2/MSH6 were 11.92% (88/797) and 4.14% (33/797), respectively. The association of clinicopathological characteristics with MMR status is presented in [Table 2](#table-2){ref-type="table"}. The proportion of dMMR was higher in patients \<50 years old (*p* \< 0.001). A higher rate of dMMR was found in stage II cancers (19.02%, *p* = 0.019). dMMR status was also associated with mucinous production (*p* \< 0.001), poor differentiation (*p* \< 0.001) and localization of the tumor to the right side of the colon (*p* \< 0.001). dMMR patients had a higher propensity to bowel wall invasion (*p* = 0.018).

10.7717/peerj.4341/table-2

###### Correlations between mismatch repair protein deficiency and clinicopathological characteristics (*n* = 797).

![](peerj-06-4341-g006)

  Characteristics             Number   dMMR          MLH1/ PMS2   MSH2/MSH6                          
  --------------------------- -------- ------------- ------------ ------------ --------- ----------- -----------------------------------------
  Gender                                                                                             
  Male                        495      73 (14.75)    0.662        52 (10.51)   0.561     21 (4.24)   0.853
  Female                      302      48 (15.89)                 36 (11.92)             12 (3.97)   
  Age                                                                                                
  \<50                        99       29 (29.29)    \<0.001      23 (23.23)   \<0.001   6 (6.06)    0.284[^\*^](#table-2fn1){ref-type="fn"}
  ≥50                         698      92 (13.18)                 65 (9.31)              27 (3.87)   
  Location                                                                                           
  Right side colon            173      61(35.26)     \<0.001      43 (24.86)   \<0.001   18 (10.4)   \<0.001
  Left side colon             185      25 (13.51)                 18 (9.73)              7 (3.78)    
  Rectum                      439      35 (7.97)                  27 (6.15)              8 (1.82)    
  Mucin production                                                                                   
  With                        131      36 (27.48)    \<0.001      25 (19.08)   \<0.001   11 (8.4)    0.007
  Without                     666      85 (12.76)                 63 (9.46)              22 (3.3)    
  Tumor differentiation                                                                              
  Poor                        134      36 (26.87)    \<0.001      24 (17.91)   \<0.001   12 (8.96)   0.012[^\*^](#table-2fn1){ref-type="fn"}
  Moderate                    589      71 (12.05)                 51(8.66)               20 (3.39)   
  Well                        31       4 (12.9)                   3 (9.68)               1 (3.23)    
  Unknown                     43                                                                     
  Tumor stage                                                                                        
  I                           94       6 (6.38)      0.019        5 (5.32)     0.110     1 (1.06)    0.288[^\*^](#table-2fn1){ref-type="fn"}
  II                          326      62 (19.02)                 45 (13.81)             17 (5.21)   
  III                         301      41 (13.62)                 30 (9.97)              11 (3.65)   
  IV                          76       12 (15.79)                 8 (10.52)              4 (5.26)    
  Bowel wall invasion (T)                                                                            
  T1                          20       3 (15)        0.018        2 (10)       0.139     1 (5)       0.067[^\*^](#table-2fn1){ref-type="fn"}
  T2                          102      5 (4.9)                    5 (4.9)                0 (0)       
  T3                          334      59 (17.66)                 44 (13.17)             15 (4.49)   
  T4                          341      54 (15.83)                 37 (10.85)             17 (4.98)   
  Lymph node metastasis (N)                                                                          
  N0                          445      74 (16.63)    0.192        54 (12.13)   0.354     20 (4.49)   0.583
  N1                          200      31 (15.5)                  22 (11)                9 (4.5)     
  N2                          152      16 (10.53)                 12 (7.89)              4 (2.63)    
  Distant metastasis (M)                                                                             
  M0                          721      110 (15.26)   0.550        80 (12.13)   0.88      30 (4.16)   0.929[^\*^](#table-2fn1){ref-type="fn"}
  M1                          76       11 (14.47)                 8 (10.53)              3 (3.95)    
  Lymphovascular invasion                                                                            
  Yes                         335      47 (14.03)    0.451        35 (10.45)   0.679     12 (3.58)   0.481
  No                          457      73 (15.97)                 52 (11.38)             21 (4.59)   
  Unknown                     5                                                                      
  Alcohol intake                                                                                     
  Ever                        162      19 (11.72)    0.170        13 (8.02)    0.170     6 (3.7)     0.755
  Never                       635      102 (16.06)                75 (11.81)             27 (4.25)   
  Smoking                                                                                            
  Ever                        263      35 (13.31)    0.170        24 (9.13)    0.226     11 (4.18)   0.967
  Never                       534      86 (16.1)                  64 (11.98)             22 (4.12)   
  Colorectal family history                                                                          
  Yes                         48       11 (22.92)    0.071        5 (10.42)    0.795     6 (12.5)    0.016[^\*^](#table-2fn1){ref-type="fn"}
  No                          335      44 (13.13)                 32 (9.55)              12 (3.58)   
  Unknown                     414                                                                    

**Notes.**

Fisher's exact test was used.

Although dMMR tumors were present more often in patients with CRC family history, no significant difference (22.92% vs 13.13%, *p* \> 0.05) was found in this study. The loss of MSH2/MSH6 expression was more often observed in patients with CRC family history (12.5% vs 3.58%, *p* = 0.016). In other respects, the patients with tumors exhibiting dMMR were similar to those exhibiting pMMR.

*RAS* gene mutation and associations with clinicopathological characteristics
-----------------------------------------------------------------------------

*RAS* status was tested from 813 patients. The mutation rates of *KRAS* and *NRAS* were 42.56% (346/813) and 3.69% (30/813), respectively. There were three patients demonstrating mutation in both *KRAS* and *NRAS*. Patients suffering from tumors with mucinous production had a higher incidence of *KRAS* mutation compared with those having tumors without mucinous production (54.89% vs 40.18%, *p* = 0.002). A higher rate of *KRAS* mutation was found in stage II (48.49%) compared with that in stage I, stage III and stage IV (36.84%, 40.45%, 34.52%, respectively) cancers (*p* = 0.023) and in non-smokers compared with smokers (46.6% vs34.98%, *p* = 0.001). Patients with CRC family history also showed higher rate of *KRAS* mutation (54.17% vs 37.39%, *p* = 0.013). Tumors with *RAS* mutation showed lower propensity to lymph node metastasis (*p* = 0.006) and distant metastasis (*p* = 0.048). No significant associations between *KRAS* mutation and other clinicopathological characteristics were found in the present study. Meanwhile, *NRAS* mutation was not significantly associated with any clinicopathological characteristics ([Table 3](#table-3){ref-type="table"}).

Correlations between *RAS* mutation and MMR status
--------------------------------------------------

*RAS* mutation rate was slightly higher in pMMR tumors than in dMMR tumors, but failed to reach a significant difference (46.3% vs 44.63%, *p* \> 0.05). There was also no obvious correlation between MMR status and *KRAS* mutation (42.3% vs 44.63%, *p* \> 0.05). No *NRAS* mutation was detected in dMMR tumors. Compared with dMMR tumors, pMMR tumors had a higher propensity to harbor *NRAS* mutation (*p* = 0.009, [Table 4](#table-4){ref-type="table"}). The distribution of MMR and *KRAS* status is shown in [Supplemental Information 3](#supp-3){ref-type="supplementary-material"}. Correlation between *KRAS* gene mutation and clinicopathological characteristics in dMMR tumors is summarized in [Table 5](#table-5){ref-type="table"}. No significant association between *KRAS* mutation and any clinicopathological characteristics were found in dMMR tumors.

Prognostic value of dMMR and *RAS* mutation in stage I--III CRC
---------------------------------------------------------------

Of the 813 followed-up patients, 729 patients were diagnosed with stage I--III CRC, including 95 stage I patients, 332 stage II patients and 302 stage III patients. dMMR and *RAS* mutation were not prognostic for DFS and OS in stage I--III CRC ([Fig. 3](#fig-3){ref-type="fig"}). Of the 121 dMMR patients, 109 patients were diagnosed with stage I--III CRC and 45.87% (50/109) patients harbored *KRAS* mutation. However, *KRAS* mutation was not prognostic factor for these patients ([Fig. 4](#fig-4){ref-type="fig"}).

10.7717/peerj.4341/table-3

###### Correlations between *RAS* gene mutations and clinicopathological characteristics (*n* = 813).
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  Characteristics             Number   *RAS*         *KRAS*   *NRAS*                            
  --------------------------- -------- ------------- -------- ------------- ------- ----------- -----------------------------------------
  Gender                                                                                        
  Male                        506      221 (43.68)   0.105    204 (40.32)   0.097   19 (3.75)   0.9
  Female                      307      152 (49.51)            142 (46.25)           11 (3.58)   
  Age                                                                                           
  \<50                        100      38 (38)       0.091    37 (37)       0.23    1 (1)       0.161[^\*^](#table-3fn1){ref-type="fn"}
  ≥50                         713      335 (46.98)            309 (43.34)           29 (4.07)   
  Location                                                                                      
  Right side colon            181      91 (50.28)    0.178    88 (48.62)    0.097   3 (1.66)    0.164
  Left side colon             189      77 (40.74)             71 (37.57)            6 (3.17)    
  Rectum                      443      205 (46.28)            187 (42.21)           21 (4.74)   
  Mucin production                                                                              
  With                        133      74 (55.64)    0.014    73 (54.89)    0.002   1 (0.75)    0.087
  Without                     680      299 (43.97)            273 (40.18)           29 (4.22)   
  Tumor differentiation                                                                         
  Poor                        138      55 (39.86)    0.315    54 (39.13)    0.604   1 (0.72)    0.093
  Moderate                    599      276 (46.08)            251 (41.9)            28 (4.67)   
  Well                        33       17 (51.52)             16 (48.48)            1 (3.03)    
  Unknown                     43                                                                
  Tumor stage                                                                                   
  I                           95       41 (43.16)    0.031    35 (36.84)    0.023   6 (6.32)    0.18[^\*^](#table-3fn1){ref-type="fn"}
  II                          332      170 (51.2)             161 (48.49)           9 (2.71)    
  III                         302      133 (44.04)            122 (40.4)            14 (4.64)   
  IV                          84       29 (34.52)             28 (34.52)            1 (1.19)    
  Bowel wall invasion (T)                                                                       
  T1                          21       9 (42.86)     0.36     8 (38.1)      0.158   1 (4.76)    0.36[^\*^](#table-3fn1){ref-type="fn"}
  T2                          104      40 (38.46)             34 (32.69)            6 (5.77)    
  T3                          336      154 (45.83)            146 (43.45)           9 (2.68)    
  T4                          352      170 (48.3)             158 (44.89)           14 (3.98)   
  Lymph node metastasis (N)                                                                     
  N0                          458      224 (48.91)   0.006    209 (45.63)   0.079   15 (3.28)   0.265
  N1                          203      88 (43.35)             83 (40.89)            6 (2.96)    
  N2                          152      61 (40.13)             54 (35.53)            9 (5.92)    
  Distant metastasis (M)                                                                        
  M0                          729      343 (47.05)   0.048    317 (43.48)   0.116   29 (3.98)   0.353[^\*^](#table-3fn1){ref-type="fn"}
  M1                          84       30 (35.71)             29 (34.52)            1 (1.19)    
  Lymphovascular invasion                                                                       
  Yes                         339      157 (46.31)   0.763    145 (42.77)   0.825   14 (4.13)   0.623
  No                          462      209 (45.24)            194 (41.99)           16 (3.46)   
  Unknown                     12                                                                
  Alcohol intake                                                                                
  Ever                        165      67 (40.61)    0.128    63 (38.18)    0.203   5 (3.03)    0.615
  Never                       648      306 (47.22)            283 (43.67)           25 (3.86)   
  Smoking                                                                                       
  Ever                        283      109 (38.52)   0.002    99 (34.98)    0.001   10 (3.53)   0.863
  Never                       530      264 (49.81)            247 (46.6)            20 (3.77)   
  Colorectal family history                                                                     
  Yes                         48       28 (58.33)    0.017    26 (54.17)    0.013   3 (6.25)    0.178[^\*^](#table-3fn1){ref-type="fn"}
  No                          337      135 (40.95)            126 (37.39)           9 (2.67)    
  Unknown                     428                                                               

**Notes.**

Fisher's exact test was used.

10.7717/peerj.4341/table-4

###### Correlations between mismatch repair protein deficiency and RAS status (*n* = 797).
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  MMR status             *RAS*            *KRAS*   *NRAS*                                   
  ---------------------- ---------------- -------- ---------------- ------- --------------- -----------------------------------------
  dMMR                   54/121 (44.63)   0.734    54/121 (44.63)   0.635   0/121 (0)       0.009[^\*^](#table-4fn1){ref-type="fn"}
  MHL1/PMS2 deficiency   39/88 (44.32)    0.725    39/88 (44.32)    0.875   0/88 (0)        0.044[^\*^](#table-4fn1){ref-type="fn"}
  MSH2/MSH6 deficiency   15/33 (45.45)    0.999    15/33 (45.45)    0.72    0/33 (0)        0.391[^\*^](#table-4fn1){ref-type="fn"}
  pMMR                   313/676 (46.3)            286/676 (42.3)           30/676 (4.43)   

**Notes.**

Fisher's exact test was used.

10.7717/peerj.4341/table-5

###### Correlations between *KRAS* gene mutations and clinicopathological characteristics in dMMR tumors (*n* = 121).

![](peerj-06-4341-g009)

  Characteristics             Number   *KRAS*       *P* value
  --------------------------- -------- ------------ -----------------------------------------
  Gender                                            
  Male                        73       31 (42.47)   0.555
  Female                      48       23 (47.91)   
  Age                                               
  \<50                        29       11 (37.93)   0.405
  ≥50                         92       43 (46.74)   
  Location                                          
  Right side colon            61       26 (42.62)   0.891
  Left side colon             25       12 (48)      
  Rectum                      35       16 (45.71)   
  Mucin production                                  
  With                        36       20 (55.56)   0.116
  Without                     85       34 (40)      
  Tumor differentiation                             
  Poor                        36       10 (27.78)   0.099[^\*^](#table-5fn1){ref-type="fn"}
  Moderate                    71       35 (49.3)    
  Well                        4        2 (50)       
  Unknown                     10                    
  Tumor stage                                       
  I                           6        2 (33.33)    0.277[^\*^](#table-5fn1){ref-type="fn"}
  II                          62       33 (53.2)    
  III                         41       15 (36.59)   
  IV                          12       4 (33.33)    
  Bowel wall invasion (T)                           
  T1                          3        2 (66.67)    0.179[^\*^](#table-5fn1){ref-type="fn"}
  T2                          5        0 (0)        
  T3                          59       26 (44.07)   
  T4                          54       26 (48.15)   
  Lymph node metastasis (N)                         
  N0                          74       38 (51.35)   0.056
  N1                          31       13 (41.94)   
  N2                          16       3 (18.75)    
  Distant metastasis (M)                            
  M0                          110      50 (45.45)   0.753[^\*^](#table-5fn1){ref-type="fn"}
  M1                          11       4 (36.36)    
  Lymphovascular invasion                           
  Yes                         47       21 (44.68)   0.927
  No                          73       32 (43.83)   
  Unknown                     1                     
  Alcohol intake                                    
  Ever                        19       9 (47.37)    0.855
  Never                       102      46 (45.1)    
  Smoking                                           
  Ever                        35       14 (40)      0.514
  Never                       86       40 (46.51)   
  Colorectal family history                         
  Yes                         11       5 (45.45)    0.589
  No                          44       24 (54.55)   
  Unknown                     66                    

**Notes.**

Fisher's exact test was used.

![Survival curves for disease free survival (DFS) and overall survival (OS) in stage I--III colorectal carcinoma according to dMMR or RAS status.\
(A) Disease free survival (DFS) according to dMMR status; (B) overall survival (OS) according to dMMR status; (C) DFS according to KRAS status; (D) OS according to KRAS status; (E) DFS according to NRAS status; (F) OS according to NRAS status.](peerj-06-4341-g003){#fig-3}

![Survival curves for disease free survival (DFS) and overall survival (OS) in stage I--III dMMR colorectal carcinoma according to KRAS status.\
(A) Disease free survival (DFS) according to KRAS status; (B) overall survival (OS) according to KRAS status.](peerj-06-4341-g004){#fig-4}

Discussion
==========

As prognostic and predictive biomarkers, MMR deficiency and *RAS* mutation are important for clinical treatment and prognosis of CRC patients. Compared with pMMR, patients with dMMR CRCs are reported to have unique clinicopathological characteristics such as poor differentiation, early stage, increased tumor-infiltrating lymphocytes and better clinical outcome ([@ref-2]; [@ref-27]; [@ref-42]). The *RAS* gene is a predictive biomarker for the resistance to anti-EGFR monoclonal antibody (MoAb) treatment in mCRCs ([@ref-1]; [@ref-41]). However, geographic and racial differences between Chinese and other countries were reported ([@ref-19]; [@ref-21]; [@ref-26]; [@ref-53]; [@ref-54]), which need to be validated with large sample amounts. Furthermore, data regarding *RAS* mutation frequency and dMMR CRC is not consistent in China. Thus, we designed this study in the Chinese population aiming to explore the relationship between the *RAS* mutation, MMR status and clinicopathological parameters, also expecting to find some prognostic and predictive biomarkers for CRC.

Our results demonstrated an overall MMR deficiency rate of 15.18%, which is within the established range of 15--21% ([@ref-16]; [@ref-52]; [@ref-4]; [@ref-8]), but slightly higher than that reported from other Chinese populations ([@ref-19]; [@ref-23]; [@ref-54]). Reports from Korea ([@ref-24]) and Japan ([@ref-25]) which used PCR-based MSI testing also showed that the frequencies of MSI-H CRCs were around 10%. This discrepancy can be explained by the different detective methods to some extent. Compared with PCR-based MSI testing examination, immunohistochemistry is thought to be easily available and time-saving. Furthermore, immunohistochemistry may detect MMR-deficient cases that can be potentially missed by PCR-based MSI testing ([@ref-50]).

Correlations between dMMR status and clinicopathological characteristics were controversial ([@ref-21]; [@ref-23]; [@ref-42]; [@ref-51]). Reports from three independent Chinese groups ([@ref-19]; [@ref-23]; [@ref-54]) indicated that dMMR had specific associations such as female gender, right sided colon tumors and mucious tumors. In a study including 1,063 CRCs, [@ref-30] observed that MSI was associated not only with gender, tumor location and mucin production, but also with tumor differentiation and tumor stage. In our current study, we found patients younger than 50 tended to be dMMR. These diverse findings may be attributed to different criteria for age division, ethnicities, environmental factors as well as the specificity and sensitivity of the detection methods.

In our study, there was a correlation between MSH2/MSH6 deficiency and family history of CRC, but not MLH1/PMS2 deficiency. In addition, according to the Bethesda criteria ([@ref-3]), 12 CRCs were diagnosed with LS. In MSH2/MSH6 deficient CRCs, 33.3% (6/18) were LS, while in MLH1/PMS2 defective cases, 13.95% (6/43) were LS, suggesting MSH2/MSH6 deficient patients had higher opportunity to be diagnosed with LS. Some of the recent studies may help to explain this finding: the majority dMMR CRCs were caused by inactivation of MLH1 and more than 70% MLH1 deficiency was caused by *MLH1* promoter hypermethylation ([@ref-18]), which could distinguish sporadic dMMR CRCs from LS cases, therefore, most MLH1 defective tumors were sporadic CRC. Another interesting phenomenon in our investigation is that we found most patients' family medical history was unclear and they did not know whether other family members had polyps removed, moreover, many cancers might be prevented by early stage colonoscopy, so the family history may be deceptive ([@ref-17]). Therefore, screening strategy based on family history may be improper. All patients with newly diagnosed CRC should be screened for LS ([@ref-17]). Inconsistent with previous studies, which indicated that patients with dMMR tumors had significantly better survival than that of pMMR patients ([@ref-11]; [@ref-27]; [@ref-28]), our study showed that dMMR was not a prognostic factor for patients with stage I--III CRC, although the incidence of dMMR in stage III disease was lower, suggesting that dMMR tumors had lower propensity to metastasize.

In the present study, the mutation rates of *KRAS* and *NRAS* are 42.56% and 3.69%, respectively. The *KRAS* mutation rate is significantly higher than the value of 20.7% among 314 CRC patients from Taiwan, China ([@ref-32]), 22% among 202 CRC patients from the England ([@ref-35]), 30.1% among 392 CRC patients from Switzerland ([@ref-58]), but similar to that previously reported in Guangzhou, China (43.9%, 25/57) ([@ref-33]). Several factors may lead to such differences, such as sample size, dietary and lifestyle factors, as well as racial and/or environmental differences. Furthermore, we detected the coding sequence of codon12 and codon13 in exon 2 of the *KRAS* gene, which may help to explain the higher percentage of *KRAS* mutation than those detected in codon12 only. Except for exon 2, recent studies have shown 5--10% of tumors harbored exon 3 or exon 4 mutation ([@ref-22]; [@ref-30]), which would also result in resistance to anti-EGFR inhibitors. Therefore, extending the detection spectrum of *RAS* might help to optimize the selection of the CRC patients to receive anti-EGFR MoAbs.

The frequency of *KRAS* mutation has been reported to be associated with age, gender, differentiation and tumor stage ([@ref-14]; [@ref-29]; [@ref-54]; [@ref-55]; [@ref-57]). Inconsistent with these results, our study showed that *KRAS* mutation was associated with mucin production, tumor stage, non-smoking and CRC family history. *RAS* mutated tumors showed lower propensity to lymph node and distant metastasis. No convincing evidence demonstrates that *KRAS* mutation is an independent prognostic factor for CRC ([@ref-23]; [@ref-38]; [@ref-46]; [@ref-55]). In the present study, no associations of *KRAS* mutation with DFS and OS were found in patients with stage I--III CRC. Further studies based on longer follow-up time and larger sample size are needed to confirm this conclusion.

In our study, the percentage of the four tumor subgroups, including dMMR/*KRAS* mutation, dMMR/*KRAS* wild-type, pMMR/*KRAS* mutation and pMMR/*KRAS* wild-type tumors was 6.78%, 8.4%, 35.88%, 48.94%, respectively, which is similar to the data reported by a study from Beijing, China ([@ref-54]). According to recent reports ([@ref-36]; [@ref-45]), patients with a MSS/*KRAS* mutant tumor had the worst survival than the other three groups. Therefore, dMMR and *KRAS* markers may provide a foundation for developing a molecular prognostic scoring system for CRC patients in the future.

Previous studies have shown that pMMR patients tended to harbor more *KRAS* mutation than dMMR patients ([@ref-35]; [@ref-54]). One hypothesis for this result is that *BRAF* and *KRAS* mutations were almost mutually exclusive in CRC and MSI tumors are more likely to harbor a *BRAF* mutation, so MSS tumors might harbor more *KRAS* mutations ([@ref-35]). However, in the present study, we did not find any differences in *KRAS* mutation between pMMR and dMMR tumors, and further studies based on larger sample size are needed to explore this controversy in Chinese CRCs.

Additionally, our study provided an opportunity to investigate the status of *KRAS* mutation in Chinese dMMR patients. *KRAS* mutation presented in 44.63% dMMR patients in our study, similar to previous studies in western countries ([@ref-8]; [@ref-37]). All of these results indicate that *KRAS* mutation could be quite common in dMMR tumors. There were no associations between *KRAS* mutation and clinicopathologic characteristics in dMMR tumors. A study conducted by [@ref-36] indicated that *KRAS* status was an independent prognostic factor in early stage MSI CRC patients. Moreover, MSI patients with wild-type *KRAS* and *BRAF* tumors have more favorable prognosis than patients with mutated *KRAS* or *BRAF* tumors in early stage CRC ([@ref-9]; [@ref-40]). However, we did not find *KRAS* mutation as a prognostic factor for dMMR patients with stage I--III CRC.

*NRAS*, as one of the *RAS* family, showed close relations with *KRAS*. Unlike *KRAS*, *NRAS* mutation was rarely detected in CRC patients. In our study, the mutation rate of *NRAS* was 3.69%, similar to previous reports ([@ref-5]; [@ref-20]; [@ref-38]; [@ref-39]). Moreover, we observed 25/388 *KRAS* wild-type tumors with *NRAS* mutation, which can partially help to explain the resistance to anti-EGFR MoAb in some *KRAS* wild-type patients. Considering the heavy financial burden in MoAb treatment in CRC patients, *NRAS* mutation should be tested before MoAb treatment in *KRAS* wild-type tumors. Another interesting phenomenon is that no *NRAS* mutation was detected in dMMR patients, which suggested *NRAS* mutation might be mutually exclusive with dMMR. Meanwhile, *NRAS* mutation was not significantly associated with any clinicopathologic characteristics in our study.

However, our results should be elucidated with consideration of its limitations: first, the sample size was relatively small, rendering some findings inconclusive; second, we used a commercially available kit authenticated by China Food and Drug Administration (CFDA) and the mutation subgroups were uncertain. A study conducted by [@ref-30] demonstrated that mutation in *KRAS* codon12 was associated with significantly poorer outcome than mutations elsewhere or wild-type *KRAS*. Therefore, the subgroup of mutation codons should be carefully explored in future; third, we did not collect data of clinical management, therefore, the influence of clinical treatment for survival was uncertain.

Conclusion
==========

In conclusion, this was an exploratory analysis of correlations between *RAS* mutation and MMR status with clinicopathological characteristics in Eastern Chinese CRC patients. The status of these molecular markers, involving MLH1/PMS2, MSH2/MSH6, *KRAS* and *NRAS* mutation, reflects the specific clinicopathological characteristics of CRC. More comprehensive molecular classification and survival analysis should be explored in future experiments.
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